Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pacritinib - CTI BioPharma

Next Previous
Drug Profile

Pacritinib - CTI BioPharma

Alternative Names: ENPAXIQ; Epjevy; ONX-0803; Pacritinib citrate - CTI BioPharma; Pacritinibum; SB-1518; VONJOTM

Latest Information Update: 23 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator S*BIO
  • Developer Cardiff University; CTI BioPharma; National Cancer Research Institute; S*BIO
  • Class Antineoplastics; Aza compounds; Benzene derivatives; Ethers; Macrocyclic compounds; Polycyclic bridged compounds; Pyrimidines; Pyrrolidines; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Interleukin-1 receptor-associated kinase inhibitors; Janus kinase-2 inhibitors; Macrophage colony stimulating factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelofibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Myelofibrosis
  • Phase II Graft-versus-host disease
  • Discontinued Acute myeloid leukaemia; Chronic myeloid leukaemia; Colorectal cancer; Haematological disorders; Lymphoma; Myelodysplastic syndromes; Myeloproliferative disorders; SARS-CoV-2 acute respiratory disease

Most Recent Events

  • 19 Dec 2023 CTI Biopharma completes a phase I drug-drug interaction trial (In volunteers) in USA (NCT05657613)
  • 09 Dec 2023 Updated efficacy data from the phase III PERSIST-2 trial in Myelofibrosis presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
  • 26 Jun 2023 CTI BioPharma has been acquired by Swedish Orphan Biovitrum
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top